Mid-cap health care company Legend Biotech has moved -1.3% this afternoon, reaching $66.82 per share. In contrast, the average analyst target price for the stock is $88.27.
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. The company is based in the United States.
What to Consider if You Are Thinking of Buying Legend Biotech:
-
Legend Biotech has moved 48.0% over the last year.
-
LEGN has a forward P/E ratio of -28.0 based on its EPS guidance of -2.39.
-
Over the last 2 years, earnings per share (EPS) have been growing at a compounded average rate of -12.9%.
-
Its Price to Book (P/B) ratio is 8.61
Legend Biotech Has an Unconvincing Cash Flow History
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-03-31 | -198,465 | -47,108 | -151,357 | 12.63 |
| 2021-04-02 | -223,005 | -49,775 | -173,230 |
Legend Biotech's recent cash flow history is disappointing. They've averaged $-162.29 Million over the last 2 years while displaying a coefficient of variability of 244917602.9%. During this time, they grew at a -0.0% compounded yearly rate
